ALLEGED SHIPMENT: From the States of Georgia and Pennsylvania into the State of South Carolina, of quantities of *pentobarbital sodium capsules* and *Dexedrine Sulfate tablets.*

ALLEGED VIOLATION: On or about April 5, 14, 26, and 28, 1950, while the drugs were being held for sale after shipment in interstate commerce, various quantities of the drugs were repacked and sold without a physician's prescription, which acts resulted in the repackaged drugs being misbranded.

The Frierson Drug Store was charged with causing the acts of repacking and sale of the drugs involved in each of the six counts of the information; and, in addition, Frederick J. Felder in each of five counts of the information and Harley S. Martin in one count of the information were charged with causing such acts to be done in connection with the drugs involved in those counts.

NATURE OF CHARGE: Misbranding, Sections 502 (b) (1) and (2), the repackaged drugs failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor, and statements of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs failed to bear any directions for use.

Further misbranding, Section 502 (d), the *pentobarbital sodium capsules* contained a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit forming; and the repackaged capsules bore no label containing the name, and quantity or proportion of such derivative and in juxtaposition therewith the statement "Warning—May be habit forming."

Further misbranding, Section 502 (e) (1), the repackaged *Dexedrine Sulfate tablets* failed to bear a label containing the common or usual name of the drug.

DISPOSITION: August 8, 1951. Pleas of guilty having been entered, the court imposed fines of $100 against the corporation and $50 against each of the individuals.

3557. Misbranding of pentobarbital sodium capsules, Benzedrine Sulfate tablets, Dexedrine Sulfate tablets, and sulfadiazine tablets. U. S. v. Medley Drug Store and Raymond R. Medley. Pleas of guilty. Fine of $70 against defendants jointly. (F. D. C. No. 30568. Sample Nos. 76974–K, 76976–K, 77605–K, 77764–K, 77765–K, 77769–K, 78212–K.)

INFORMATION FILED: May 25, 1951, Western District of Missouri, against the Medley Drug Store, a partnership, Lebanon, Mo., and Raymond R. Medley, a partner in the partnership.

INTERSTATE SHIPMENT: From the States of Illinois and Pennsylvania into the State of Missouri, of quantities of *Pentobarbital sodium capsules, Benzedrine Sulfate tablets, Dexedrine Sulfate tablets,* and *Sulfadiazine tablets.*

ALLEGED VIOLATION: On or about May 21, June 12, and July 5, 8, and 12, 1950, while the drugs were being held for sale at the Medley Drug Store after shipment in interstate commerce, the defendants caused various quantities of the drugs to be repacked and sold without a physician's prescription, which acts resulted in the repacked drugs being misbranded.

NATURE OF CHARGE: Misbranding, Section 502 (b) (2), the repackaged drugs failed to bear labels containing statements of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs failed to bear adequate directions for use.

Further misbranding, Section 502 (b) (1), the repackaged *Benzedrine Sulfate tablets, Dexedrine Sulfate tablets,* and *sulfadiazine tablets* failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor.

Further misbranding, Section 502 (d), the repackaged *pentobarbital sodium capsules* contained a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit forming; and the label of the repackaged capsules failed to bear the name, and quantity or proportion of such derivative and in juxtaposition therewith the statement "Warning—May be habit forming."

Further misbranding, Section 502 (f) (2), the labeling of the repackaged *sulfadiazine tablets* bore no warning against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration.

DISPOSITION: October 1, 1951. Pleas of guilty having been entered, the court imposed a fine of $70 against the defendants jointly.

3558. Misbranding of pentobarbital sodium capsules, Dexedrine Sulfate tablets, thyroid tablets, diethylstilbestrol capsules, and sulfadiazine tablets. U. S. v. Burley F. Jones (Sidney's Drug Store), Jay J. Gentry, and Cecil N. Gammon. Pleas of guilty. Fine of $100 against defendants jointly. (F. D. C. No. 30566. Sample Nos. 76957–K, 76959–K, 76962–K, 76979–K, 77036–K, 77145–K, 77146–K, 77766–K, 77771–K, 78215–K.)

INFORMATION FILED: June 22, 1951, Western District of Missouri, against Burley F. Jones, trading as Sidney's Drug Store, Lebanon, Mo., and against Jay J. Gentry, an employee of the store, and Cecil N. Gammon, a pharmacist for the store.

INTERSTATE SHIPMENT: From the States of Illinois, Pennsylvania, and Michigan, into the State of Missouri, of quantities of *pentobarbital sodium capsules, Dexedrine Sulfate tablets, thyroid tablets, diethylstilbestrol capsules,* and *sulfadiazine tablets.*

ALLEGED VIOLATION: On or about May 21, June 12 and 17, and July 5, 6, and 12, 1950, while the drugs were being held for sale at Sidney's Drug Store after shipment in interstate commerce, various quantities of the drugs were repacked and sold without a physician's prescription, which acts resulted in the repackaged drugs being misbranded.

Burley F. Jones was charged with causing the acts of repacking and sale of the drugs involved in each of the ten counts of the information; and, in addition, Jay J. Gentry in each of two counts of the information and Cecil N. Gammon in one count of the information were charged with causing such acts to be done in conection with the drugs involved in those counts.

NATURE OF CHARGE: Misbranding, Section 502 (b) (2), the repackaged drugs failed to bear labels containing statements of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs failed to bear adequate directions for use.

Further misbranding, Section 502 (e) (1), the repackaged *Dexedrine Sulfate tablets* failed to bear a label containing the common or usual name of the drug.

Further misbranding, Section 502 (d), the *pentobarbital sodium capsules* contained a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit forming; and the label of the repackaged capsules failed to bear the name, and quantity or proportion